The implementation of the Kerubin solution revolves around a central and crucial objective: to help the doctor intervene in time and to better manage the onset of adverse effects.
The management of chronicity requires a considerable commitment of resources and continuity of assistance.
Kidney cancer accounts for 4% of all cancers. For the most recently diagnosed cases, survival is five years for about 70% of patients.
To date, there are no tumor markers for diagnosis that is mainly based on imaging, such as ultrasound or computed tomography (CT).